Physician profile
Daniel M Appelbaum
NPI 1750344487
$4,247.22
in general payments reported to CMS, 2019-2025
38 companies · $590 in 2025
The $590 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $254 · 2021: $637 · 2022: $931 · 2023: $719 · 2024: $706 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,014.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $636.68 | 2019-2025 | Repatha, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $503.05 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $496.61 | 2021-2025 | |
| Novo Nordisk INC | $450.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $287.28 | 2019-2024 | Lokelma, Farxiga |
| Abbott Laboratories | $257.18 | 2019-2025 | Freestyle Libre 3, Aveir, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.76 | 2019-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.52 | 2022 | |
| Merck Sharp & Dohme LLC | $120.62 | 2020-2023 | Verquvo, Steglatro |
| Opko Pharmaceuticals, LLC | $115.15 | 2024-2025 | Rayaldee |
| Pfizer INC. | $87.46 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $72.27 | 2020-2024 | Camzyos |
| Althera Pharmaceuticals LLC | $72.14 | 2021-2022 | |
| Glaxosmithkline, LLC. | $59.62 | 2022-2025 | Arexvy, Shingrix |
| Medtronic Vascular, INC. | $58.45 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Appelbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.